Literature DB >> 33089401

Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.

Huang-Chun Lien1,2, Yi-Hsuang Lee1, I-Chun Chen3,4, Ching-Hung Lin3,4,5, Tom Wei-Wu Chen3, Yueh-Tong Lu1, Yen-Shen Lu6,7.   

Abstract

Both stromal tumor-infiltrating lymphocytes (sTILs) and programmed death-ligand 1 (PD-L1) affect responses to immunotherapy; however, the extent of sTIL and PD-L1 expression within various metaplastic components in metaplastic breast carcinoma (MBC), which are critical for the characterization of immune microenvironments, remains unreported. We profiled sTIL infiltration and PD-L1 expression in different metaplastic components of specimens from 82 MBC patients. The overall positivity for high or intermediate (H/I) sTIL, immune cell-PD-L1 (IcPD-L1), and tumor cell-PD-L1 (TcPD-L1) was 34.1%, 47.6%, and 17.1%, respectively, but differences specific to MBC subtypes and each metaplastic component existed. Squamous cell carcinoma exhibited the highest positivity rates of sTIL(H/I) (50.0%) and IcPD-L1 (66.7%), while matrix-producing carcinoma had the lowest respective rates (14.3% and 28.6%). The positivity rates of sTIL(H/I) and IcPD-L1 were the highest in squamous component (Sq) and the lowest in chondroid component (Ch). All cases that had discordant sTIL categories between carcinoma of no special type (NST) and metaplastic components showed sTIL(H/I) positivity higher in Sq, but lower in spindled component (Sp) and Ch. While there was no pattern of higher IcPD-L1-positivity in Sp, six of the seven cases that were TcPD-L1-discordant between NST and Sp were TcPD-L1-positive in Sp, suggesting a trend for higher TcPD-L1 in Sp. The diagnostic predictability of total tumor IcPD-L1 positivity based on IcPD-L1 positivity in Sq and Ch was 95.2% and 33.3%, respectively. Multivariate analysis showed that sTIL(H/I) positivity, but not PD-L1 positivity, correlated with better survival. Our data implicate distinct immune microenvironments in different metaplastic components in MBC, which may have immunopathologic, diagnostic, and therapeutic significance.

Entities:  

Keywords:  Metaplastic breast carcinoma; Program death-ligand 1; Tumor-infiltrating lymphocyte

Mesh:

Substances:

Year:  2020        PMID: 33089401     DOI: 10.1007/s00428-020-02954-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  1 in total

1.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.

Authors:  Peter Schmid; Stephen Y Chui; Leisha A Emens
Journal:  N Engl J Med       Date:  2019-03-07       Impact factor: 91.245

  1 in total
  5 in total

Review 1.  The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

Authors:  Khalid El Bairi; Harry R Haynes; Elizabeth Blackley; Susan Fineberg; Jeffrey Shear; Sophia Turner; Juliana Ribeiro de Freitas; Daniel Sur; Luis Claudio Amendola; Masoumeh Gharib; Amine Kallala; Indu Arun; Farid Azmoudeh-Ardalan; Luciana Fujimoto; Luz F Sua; Shi-Wei Liu; Huang-Chun Lien; Pawan Kirtani; Marcelo Balancin; Hicham El Attar; Prerna Guleria; Wenxian Yang; Emad Shash; I-Chun Chen; Veronica Bautista; Jose Fernando Do Prado Moura; Bernardo L Rapoport; Carlos Castaneda; Eunice Spengler; Gabriela Acosta-Haab; Isabel Frahm; Joselyn Sanchez; Miluska Castillo; Najat Bouchmaa; Reena R Md Zin; Ruohong Shui; Timothy Onyuma; Wentao Yang; Zaheed Husain; Karen Willard-Gallo; An Coosemans; Edith A Perez; Elena Provenzano; Paula Gonzalez Ericsson; Eduardo Richardet; Ravi Mehrotra; Sandra Sarancone; Anna Ehinger; David L Rimm; John M S Bartlett; Giuseppe Viale; Carsten Denkert; Akira I Hida; Christos Sotiriou; Sibylle Loibl; Stephen M Hewitt; Sunil Badve; William Fraser Symmans; Rim S Kim; Giancarlo Pruneri; Shom Goel; Prudence A Francis; Gloria Inurrigarro; Rin Yamaguchi; Hernan Garcia-Rivello; Hugo Horlings; Said Afqir; Roberto Salgado; Sylvia Adams; Marleen Kok; Maria Vittoria Dieci; Stefan Michiels; Sandra Demaria; Sherene Loi
Journal:  NPJ Breast Cancer       Date:  2021-12-01

Review 2.  An Update on the Molecular Pathology of Metaplastic Breast Cancer.

Authors:  Amy E McCart Reed; Emarene M Kalaw; Sunil R Lakhani
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-02-26

3.  Combined Positive Score for Programmed Death Ligand-1 Expression and Inflammatory Microenvironment in Gastrointestinal Stromal Tumors.

Authors:  Vlad Herlea; Alexandra Roșulescu; Violeta Claudia Calotă; Vlad Croitoru; Elena Stoica Mustafa; Cătălin Vasilescu; Sorin Alexandrescu; Traian Dumitrașcu; Irinel Popescu; Simona Olimpia Dima; Maria Sajin
Journal:  Medicina (Kaunas)       Date:  2022-01-24       Impact factor: 2.430

4.  Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report.

Authors:  Yang Fu; Jie Liu; Yu Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-23       Impact factor: 5.555

5.  Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma.

Authors:  Willard Wong; Edi Brogi; Jorge S Reis-Filho; George Plitas; Mark Robson; Larry Norton; Monica Morrow; Hannah Y Wen
Journal:  NPJ Breast Cancer       Date:  2021-07-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.